ストックスクリーナーアプリを入手
4.51
0.11%
-0.03
前日終値:
$4.48
開ける：
$4.46
24時間の取引高:
17,347
Relative Volume:
0.03
時価総額：
$260.05M
収益：
$192.64M
当期純損益:
$2.51M
株価収益率:
86.07
EPS:
0.0524
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
-1.21%
1か月 パフォーマンス:
-7.73%
6か月 パフォーマンス:
-15.73%
1年 パフォーマンス:
+28.96%
1日の値動き範囲:
$4.46
$4.50
1週間の範囲:
$4.215
$4.61
52週間の値動き範囲:
$3.46
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.49 | 260.05M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.27 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
727.48 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
668.47 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.47 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-31 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
| 2021-05-12 | 開始されました | BofA Securities | Buy |
| 2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
| 2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
| 2019-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 繰り返されました | Jefferies | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-09-21 | 再開されました | Oppenheimer | Outperform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-06-27 | 再開されました | Piper Jaffray | Overweight |
| 2017-05-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Oppenheimer | Outperform |
| 2016-11-09 | 開始されました | Aegis Capital | Buy |
| 2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder - The Business Journals
HC Wainwright Reaffirms Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - Pharmaceutical Technology
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab - MSN
Vanda, Anaptys Join on Development Pact - Baystreet.ca
AnaptysBio Partners with Vanda for Imsidolimab Development - TipRanks
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab - Marketscreener.com
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab - TipRanks
Breakthrough GPP Treatment Deal: Vanda Secures Phase 3-Ready Rare Disease Drug for $15M Upfront - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug - MSN
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Washington D.C. Pharma Co. Receives FDA Acceptance - Streetwise Reports
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts - Benzinga
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts - The Business Journals
Vanda granted hearing to discuss FDA rejection of application for tradipitant - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug By Investing.com - Investing.com South Africa
Vanda granted hearing to discuss FDA rejection of application for tradipitant ( - Seeking Alpha
Vanda Pharmaceuticals Files New Drug Application - TipRanks
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA - TipRanks
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis - PR Newswire
Vanda Loses US Trade Secrets Battle Over Fanapt And Hetlioz Generics - News & Insights
US Claims Court rules Vanda’s trade secrets not so secret - BioWorld Online
Vanda Loses US Trade Secrets Battle On Fanapt And Hetlioz ANDA Products - News & Insights
Equities Analysts Issue Forecasts for VNDA FY2025 Earnings - MarketBeat
Vanda Loses Takings Clause Arguments In Trade Secret Fight - Law360
Vanda Pharmaceuticals (NASDAQ:VNDA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat
Vanda asserts FDA review of tradipitant was flawed - MSN
Insomnia Market Overall Study Report 2025-2032 | Vanda - openPR
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate - Yahoo Finance
Pugilistic Vanda Collects Another NOOH As US FDA Defends Tradipitant Turndown - News & Insights
DC Circuit Skeptical of FDA Rejection of Vanda’s Jet Lag Drug - Bloomberg Law
High Court Rejects Vanda Suit Over Medicaid Drug Definition - Bloomberg Law
Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review - BioSpace
Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner - Marketscreener.com
Vanda Pharmaceuticals Challenges FDA Over Gastroparesis Drug Rejection in Open Letter - StockTitan
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now? - Yahoo Finance
StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
4.75%
0.58%
大文字化:
|
ボリューム (24 時間):